|
62 Companies |
|
89 Products |
|
89 Products |
|
76 Mechanisms of Action |
|
2 Trials |
|
652 News |
|
| «12...234567891011121314» |
- ||||| New P2 trial: Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention) (clinicaltrials.gov) - Mar 8, 2012
P2, N=165, Completed, Sponsor: Rock Creek Pharmaceuticals, Inc.
- methimazole / Generic mfg.
Clinical: Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients (clinicaltrials.gov) - Feb 29, 2012
P=N/A, N=150, Completed, Sponsor: Mashhad University of Medical Sciences
- ||| ZY T1 / Zydus Lifesci
New P1 trial: A Clinical Study to Evaluate the Safety,Tolerability and PK of ZYT1, Following Oral Administration in Healthy Volunteers (clinicaltrials.gov) - Feb 29, 2012
P1, N=112, Active, not recruiting, Sponsor: Cadila Healthcare Limited
- Trial completion: Analgesic Efficacy of Bilateral Superficial Cervical Plexus Block in Robot-assisted Endoscopic Thyroidectomy Using a Transaxillary Approach (clinicaltrials.gov) - Feb 25, 2012
P=N/A, N=97, Completed, Sponsor: Yonsei University
Recruiting --> Completed
- ||| buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment open, Metastases: A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies (clinicaltrials.gov) - Feb 23, 2012
P1, N=53, Recruiting, Sponsor: Emory University
Recruiting --> Completed Not yet recruiting --> Recruiting
- | thyroxine / Generic mfg.
New P4 trial: Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers (clinicaltrials.gov) - Feb 20, 2012
P4, N=26, Completed, Sponsor: GlaxoSmithKline
- Enrollment open: Thyroid Disease Serum Repository (clinicaltrials.gov) - Feb 20, 2012
P=N/A, N=1000, Recruiting, Sponsor: University of Arkansas
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- thyroxine / Generic mfg.
Trial initiation date: Selenium Supplementation in Pregnancy (clinicaltrials.gov) - Feb 14, 2012
P4, N=150, Recruiting, Sponsor: University of Roma La Sapienza
Active, not recruiting --> Recruiting Initiation date: Nov 2011 --> Apr 2012
- Trial initiation date: Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy (clinicaltrials.gov) - Feb 14, 2012
P=N/A, N=5, Terminated, Sponsor: Centre Hospitalier Universitaire de N?mes
Initiation date: Nov 2011 --> Apr 2012 Initiation date: May 2011 --> Sep 2011
- thyroxine / Generic mfg.
Enrollment change: Selenium Supplementation in Pregnancy (clinicaltrials.gov) - Feb 14, 2012
P4, N=150, Recruiting, Sponsor: University of Roma La Sapienza
Initiation date: May 2011 --> Sep 2011 N=250 --> 150
- dexamethasone injection / Generic mfg.
New P1 trial: Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients (clinicaltrials.gov) - Feb 14, 2012
P1, N=50, Completed, Sponsor: Xiao-Ming Mao
- Enrollment open: The Role of Elastography in the Diagnosis of Thyroid Nodules (clinicaltrials.gov) - Feb 14, 2012
P=N/A, N=187, Recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
N=250 --> 150 Not yet recruiting --> Recruiting
- Caprelsa (vandetanib) / Sanofi
Enrollment change, Metastases: A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) (clinicaltrials.gov) - Feb 9, 2012
P1/2, N=22, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=117 --> 22
- Caprelsa (vandetanib) / Sanofi
Enrollment closed, Metastases: A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) (clinicaltrials.gov) - Feb 9, 2012
P1/2, N=22, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=117 --> 22 Recruiting --> Active, not recruiting
- Tavalisse (fostamatinib) / Rigel
Enrollment change, Metastases: A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... (clinicaltrials.gov) - Feb 6, 2012
P2, N=37, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=285 --> 37
- Tavalisse (fostamatinib) / Rigel
Trial completion, Metastases: A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... (clinicaltrials.gov) - Feb 6, 2012
P2, N=37, Completed, Sponsor: National Cancer Institute (NCI)
N=285 --> 37 Recruiting --> Completed
- || thyroxine / Generic mfg.
New P2/3 trial: Supraphysiological Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression (clinicaltrials.gov) - Feb 5, 2012
P2/3, N=74, Completed, Sponsor: Charite University, Berlin, Germany
- Torisel (temsirolimus) / Pfizer
Enrollment closed: Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (clinicaltrials.gov) - Jan 31, 2012
P1, N=19, Active, not recruiting, Sponsor: University of Southern California
Recruiting --> Completed Recruiting --> Active, not recruiting
- Trial withdrawal: Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound (clinicaltrials.gov) - Jan 26, 2012
P=N/A, N=0, Withdrawn, Sponsor: University of Alabama at Birmingham
Recruiting --> Active, not recruiting Recruiting --> Withdrawn
- Enrollment change: Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound (clinicaltrials.gov) - Jan 26, 2012
P=N/A, N=0, Withdrawn, Sponsor: University of Alabama at Birmingham
Recruiting --> Withdrawn N=35 --> 0
- sorafenib / Generic mfg.
Trial initiation date: Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer (clinicaltrials.gov) - Jan 18, 2012
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
N=35 --> 0 Initiation date: Oct 2011 --> Jan 2012
- Trial completion, Surgery: Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases (clinicaltrials.gov) - Jan 18, 2012
P1, N=27, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Initiation date: Oct 2011 --> Jan 2012 Recruiting --> Completed
- lithium carbonate ER / Generic mfg.
Trial completion: Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer (clinicaltrials.gov) - Jan 3, 2012
P2, N=34, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting --> Completed Active, not recruiting --> Completed
- sorafenib / Generic mfg.
New P2 trial: Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer (clinicaltrials.gov) - Dec 28, 2011
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
- Votrient (pazopanib) / Novartis, BeiGene
Trial initiation date, Combination therapy, Surgery, Metastases: Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery (clinicaltrials.gov) - Dec 27, 2011
P1, N=24, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed Initiation date: Sep 2011 --> Dec 2011
- | Enrollment change: Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain (clinicaltrials.gov) - Dec 15, 2011
P3, N=78, Completed, Sponsor: Samsung Medical Center
Initiation date: Sep 2011 --> Dec 2011 N=44 --> 78
- | Trial completion: Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain (clinicaltrials.gov) - Dec 15, 2011
P3, N=78, Completed, Sponsor: Samsung Medical Center
N=44 --> 78 Recruiting --> Completed
- | Trial termination, Surgery: DIPAVO: Evaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea (clinicaltrials.gov) - Dec 11, 2011
P4, N=71, Terminated, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed Recruiting --> Terminated
- Enrollment change, Surgery: DIPAVO: Evaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea (clinicaltrials.gov) - Dec 11, 2011
P4, N=71, Terminated, Sponsor: University Hospital, Bordeaux
Recruiting --> Terminated N=246 --> 71
- sunitinib / Generic mfg.
Trial initiation date, Metastases: Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer (clinicaltrials.gov) - Dec 5, 2011
P2, N=35, Active, not recruiting, Sponsor: University of Washington
N=246 --> 71 Initiation date: Apr 2007 --> Jul 2007
- | acetylcysteine solution / Generic mfg.
New P4 trial: Effects of N-acetylcysteine on Low T3 Syndrome (clinicaltrials.gov) - Nov 24, 2011
P4, N=60, Recruiting, Sponsor: Federal University of Rio Grande do Sul
- ||| buparlisib (AN2025) / Novartis, Adlai Nortye
New P1 trial, Metastases: A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies (clinicaltrials.gov) - Nov 9, 2011
P1, N=53, Recruiting, Sponsor: Emory University
- Trial completion: RIT in MTC: Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma (clinicaltrials.gov) - Nov 9, 2011
P2, N=0, Completed, Sponsor: Nantes University Hospital
Initiation date: Apr 2007 --> Jul 2007 Active, not recruiting --> Completed
- | thyroxine / Generic mfg.
New P4 trial: Selenium Supplementation in Pregnancy (clinicaltrials.gov) - Nov 3, 2011
P4, N=150, Recruiting, Sponsor: University of Roma La Sapienza
- ||| Mekinist (trametinib) / Novartis, BeiGene, pazopanib / Generic mfg.
Enrollment open, Combination therapy, Metastases: Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma (clinicaltrials.gov) - Nov 2, 2011
P1, N=111, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment change: B-Receptor Signaling in Cardiomyopathy (clinicaltrials.gov) - Oct 30, 2011
P=N/A, N=99, Completed, Sponsor: Daniel Bernstein
Not yet recruiting --> Recruiting N=300 --> 99
- Trial completion: B-Receptor Signaling in Cardiomyopathy (clinicaltrials.gov) - Oct 30, 2011
P=N/A, N=99, Completed, Sponsor: Daniel Bernstein
N=300 --> 99 Recruiting --> Completed
- | Zybrestat (fosbretabulin) / Oncotelic
Trial termination, Combination therapy: FACT: Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer (clinicaltrials.gov) - Oct 27, 2011
P2/3, N=80, Terminated, Sponsor: OXiGENE
Recruiting --> Completed Active, not recruiting --> Terminated; Low rate of subject accrual
- | Zybrestat (fosbretabulin) / Oncotelic
Enrollment change, Combination therapy: FACT: Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer (clinicaltrials.gov) - Oct 27, 2011
P2/3, N=80, Terminated, Sponsor: OXiGENE
Active, not recruiting --> Terminated; Low rate of subject accrual N=180 --> 80
- | MIKA Diclofenac Spray Gel (diclofenac spraygel) / Nogra Pharma
New P4 trial: Adjuvant Treatment of Graves (clinicaltrials.gov) - Oct 18, 2011
P4, N=65, Active, not recruiting, Sponsor: Mikael Lantz
- ||| BMS-908662 / Exelixis
Trial completion: Study of XL281 in Adults With Solid Tumors (clinicaltrials.gov) - Oct 11, 2011
P1, N=180, Completed, Sponsor: Exelixis
N=180 --> 80 Recruiting --> Completed
- ||||| sorafenib / Generic mfg.
Enrollment closed, Metastases: Nexavar (clinicaltrials.gov) - Sep 26, 2011
P3, N=417, Active, not recruiting, Sponsor: Bayer
Recruiting --> Completed Recruiting --> Active, not recruiting
- | thyroxine / Generic mfg.
Enrollment open: L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Hypothyroxinemia (clinicaltrials.gov) - Sep 25, 2011
P3, N=200, Recruiting, Sponsor: Centre Hospitalier Universitaire, Amiens
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Enrollment change, FDG PET: Accuracy of FDG-PET Scanning to Diagnose Malignant Thyroid Nodules (clinicaltrials.gov) - Sep 21, 2011
P=N/A, N=84, Active, not recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting N=125 --> 84
- Enrollment closed, FDG PET: Accuracy of FDG-PET Scanning to Diagnose Malignant Thyroid Nodules (clinicaltrials.gov) - Sep 21, 2011
P=N/A, N=84, Active, not recruiting, Sponsor: Washington University School of Medicine
N=125 --> 84 Recruiting --> Active, not recruiting
- ||| Mekinist (trametinib) / Novartis, BeiGene, pazopanib / Generic mfg.
New P1 trial, Combination therapy, Metastases: Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma (clinicaltrials.gov) - Sep 20, 2011
P1, N=111, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- Biomarker, Enrollment change: Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers: The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3 (clinicaltrials.gov) - Sep 19, 2011
P=N/A, N=86, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting --> Active, not recruiting N=150 --> 86
- New P1 trial: To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer (clinicaltrials.gov) - Sep 18, 2011
P1, N=30, Active, not recruiting, Sponsor: Alberta Health Services
- Enrollment change: Thyroid Dysfunction in Head and Neck Surgery Patients (clinicaltrials.gov) - Aug 31, 2011
P=N/A, N=14, Completed, Sponsor: University of Arkansas
N=150 --> 86 N=10 --> 14
- Trial completion: Thyroid Dysfunction in Head and Neck Surgery Patients (clinicaltrials.gov) - Aug 31, 2011
P=N/A, N=14, Completed, Sponsor: University of Arkansas
N=10 --> 14 Active, not recruiting --> Completed